SCHEMBL6181669

SCHEMBL6181669

COC(=O)c1ccc(Oc2ccc(OC)cc2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CYP2C9 P11712 3/20 0.51
KDM4E B2RXH2 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
PARP10 Q53GL7 1/20 0.50
CYP3A4 P08684 2/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
HPGD P15428 2/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179412 0.90 HTT (0.58) CA1CA2CYP2C9KDM4ECYP1A2
SCHEMBL19041838 0.89 XDH (0.52) CYP2C9KDM4ECYP2C19PARP10LMNA
SCHEMBL7765927 0.86 KDM4E (0.58) CA1CA2CYP2C9KDM4ECYP1A2
SCHEMBL20556162 0.84 ALDH1A1 (0.50) KDM4ELMNAHPGDALDH1A1MAPT
SCHEMBL31557902 0.82 MEN1 (0.51) KDM4EHTTALDH1A1POLBMAPT
SCHEMBL31063578 0.82 CA1 (0.42) CA1CA2KDM4ELMNAHTT
SCHEMBL22169858 0.81 L3MBTL1 (0.52) CA1CA2KDM4EPARP10LMNA
SCHEMBL14907284 0.79 KDM4E (0.49) CA1CA2CYP2C9KDM4ECYP1A2
SCHEMBL6182518 0.78 KDM4E (0.47) CA1CA2CYP2C9KDM4ECYP1A2
SCHEMBL2188276 0.78 CA1 (0.88) CA1CA2KDM4EPARP10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919332-B2 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-19 US disclosed
EP-1507535-A1 PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-23 EP disclosed
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-18 US disclosed
WO-2003090751-A1 PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 CA1 762/4885CA2 515/4885CYP2C9 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.